CN114652762A - Pharmaceutical composition for treating oral ulcer and preparation method thereof - Google Patents

Pharmaceutical composition for treating oral ulcer and preparation method thereof Download PDF

Info

Publication number
CN114652762A
CN114652762A CN202210320631.6A CN202210320631A CN114652762A CN 114652762 A CN114652762 A CN 114652762A CN 202210320631 A CN202210320631 A CN 202210320631A CN 114652762 A CN114652762 A CN 114652762A
Authority
CN
China
Prior art keywords
tablets
pharmaceutical composition
parts
oral ulcer
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210320631.6A
Other languages
Chinese (zh)
Inventor
钱国祥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202210320631.6A priority Critical patent/CN114652762A/en
Publication of CN114652762A publication Critical patent/CN114652762A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/413—Gall bladder; Bile
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/346—Platycodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708—Rheum (rhubarb)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a pharmaceutical composition for treating oral ulcer and a preparation method thereof, wherein the pharmaceutical composition comprises the following components: acyclovir tablets, bezoar detoxicating tablets, blood circulation promoting and blood circulation promoting capsules, dexamethasone tablets, metronidazole tablets and pain relieving tablets. Preferably, the weight ratio of acyclovir tablets, bezoar detoxicating tablets, blood circulation promoting and blood circulation invigorating capsules, dexamethasone tablets, metronidazole tablets and pain relieving tablets in the pharmaceutical composition is 1:1:0.5:0.5:0.25: 0.25. The pharmaceutical composition also comprises auxiliary materials, wherein the auxiliary materials comprise vitamin B complex and vitamin C. The invention also provides a preparation method of the pharmaceutical composition for treating oral ulcer. The pharmaceutical composition for treating oral ulcer and the preparation method thereof provided by the invention have the advantages that the prepared composition can quickly diminish inflammation, relieve pain, clear away heat and toxic materials, repair oral mucosa, reduce pain of patients and shorten the healing time.

Description

Pharmaceutical composition for treating oral ulcer and preparation method thereof
Technical Field
The invention relates to a pharmaceutical composition and a preparation method thereof, in particular to a pharmaceutical composition for treating oral ulcer and a preparation method thereof.
Background
Oral ulcer, commonly known as "aphtha", is a common ulcerative injury to the oral mucosa, which is usually found in the inner labial, tongue abdomen, buccal mucosa, vestibular sulcus, soft palate, etc., where the mucosa lacks cutinization layer or has poor keratosis. Tongue ulcer refers to oral ulcer occurring on tongue and tongue abdomen. The pain is severe when the oral ulcer is attacked, the local burning pain is obvious, and serious patients can influence diet and speaking, thereby causing great inconvenience to daily life; can be used for treating halitosis, chronic pharyngitis, constipation, headache, dizziness, nausea, asthenia, dysphoria, fever, and lymphadenectasis.
Canker sores develop as a result of a combination of factors including topical trauma, stress, food, medication, malnutrition, altered hormone levels, and vitamin or trace element deficiencies. Systemic diseases, heredity, immunity and microorganisms may play an important role in the development and development of oral ulcers. If the oral ulcer is lack of trace elements such as zinc and iron, folic acid, vitamin B12 and malnutrition, the immune function can be reduced, and the possibility of oral ulcer is increased; bacteria such as streptococcus sanguis and helicobacter pylori are closely related to dental ulcer. Oral ulcers generally indicate potential systemic disease conditions in the body, and oral ulcers are associated with gastric ulcers, duodenal ulcers, ulcerative colitis, Crohn's disease, hepatitis, female menstrual periods, vitamin B malabsorption, vegetative nerve dysfunction, and the like.
Disclosure of Invention
The invention aims to provide a composition for treating oral ulcer and a preparation method thereof, the composition can rapidly relieve pain, diminish inflammation, promote tissue regeneration, clear away heat and toxic materials and rapidly repair mucous membranes, and the composition has a simple medicament formula and is economical and practical.
In order to achieve the above objects, the present invention provides a pharmaceutical composition for oral ulcer, wherein the pharmaceutical composition comprises: acyclovir tablets, bezoar detoxicating tablets, blood circulation promoting and blood circulation promoting capsules, dexamethasone tablets, metronidazole tablets and pain relieving tablets.
The pharmaceutical composition for treating oral ulcer comprises the following components in parts by weight: 80-120 parts of acyclovir tablets, 80-120 parts of bezoar detoxicating tablets, 40-60 parts of blood circulation promoting and vein relaxing capsules, 40-60 parts of dexamethasone tablets, 20-30 parts of metronidazole tablets and 20-30 parts of pain relieving tablets.
The pharmaceutical composition for treating oral ulcer comprises acyclovir tablets, bezoar detoxicating tablets, blood circulation promoting and blood circulation invigorating capsules, dexamethasone tablets, metronidazole tablets and pain relieving tablets in a weight ratio of 1:1:0.5:0.5:0.25: 0.25.
The pharmaceutical composition for treating oral ulcer further comprises an auxiliary material, wherein the auxiliary material comprises vitamin B complex and vitamin C.
The pharmaceutical composition for treating oral ulcer comprises the following auxiliary materials in parts by weight: 6-10 parts of vitamin B complex and 5-8 parts of vitamin C.
The invention also provides a preparation method of the pharmaceutical composition for treating oral ulcer, wherein the method comprises the following steps: weighing acyclovir tablets, bezoar detoxicating tablets, blood circulation promoting and vein relaxing capsules, dexamethasone tablets, metronidazole tablets and pain relieving tablets as well as compound vitamin B and vitamin C of auxiliary materials according to the proportion respectively, grinding the tablet medicines and capsule contents into powder respectively, sieving and uniformly mixing to obtain the required pharmaceutical composition.
The preparation method of the pharmaceutical composition for treating oral ulcer is characterized in that the particle size of the sieved medicinal powder is 30-40 meshes.
The preparation method of the pharmaceutical composition for treating oral ulcer comprises the steps of keeping the pharmaceutical composition in a bulk state, bottling and sealing, or filling the pharmaceutical composition into capsules, or tabletting, and finally packaging for later use.
The pharmaceutical composition for oral ulcer and the preparation method thereof provided by the invention have the following advantages:
the pharmaceutical composition for treating the oral ulcer can quickly diminish inflammation and relieve pain, repair oral mucosa, clear away heat and toxic materials, reduce pain of patients and shorten healing time. The traditional Chinese medicine composition is specially used for treating the dental ulcer, has obvious curative effect, and is simple in medicine formula, economical and practical.
Detailed Description
The following further describes embodiments of the present invention.
The invention provides a pharmaceutical composition for oral ulcer, which comprises the following components: acyclovir tablets, bezoar detoxicating tablets, blood circulation promoting and blood circulation promoting capsules, dexamethasone tablets, metronidazole tablets and pain relieving tablets.
Preferably, the pharmaceutical composition comprises the following components in parts by weight: 80-120 parts of acyclovir tablets, 80-120 parts of bezoar detoxicating tablets, 40-60 parts of blood-activating and vessel-dredging capsules, 40-60 parts of dexamethasone tablets, 20-30 parts of metronidazole tablets and 20-30 parts of pain-relieving tablets.
More preferably, the weight ratio of the acyclovir tablets, the bezoar detoxicating tablets, the blood circulation promoting and vein relaxing capsules, the dexamethasone tablets, the metronidazole tablets and the pain relieving tablets in the pharmaceutical composition is 1:1:0.5:0.5:0.25: 0.25.
The pharmaceutical composition also comprises auxiliary materials, wherein the auxiliary materials comprise vitamin B complex and vitamin C.
The auxiliary materials comprise the following components in parts by weight: 6-10 parts of vitamin B complex and 5-8 parts of vitamin C.
Wherein, the acyclovir tablets, the bezoar detoxicating tablets, the dexamethasone tablets, the metronidazole tablets, the pain relieving tablets, the vitamin B complex and the vitamin C are all normal medicines which are sold in the market and obtain the national medicine approval document number.
Acyclovir tablets, 0.1 g/tablet, are mainly used for antivirus. The indications are as follows: 1. herpes simplex virus infection: the product is orally taken for preventing initial and recurrent cases of genital herpes virus infection; 2. herpes zoster: treatment of immunocompromised shingles and mild cases of immunodeficiency; 3. treating varicella of immunodeficiency patients.
Bezoar detoxicating tablet, 0.27 g/tablet, Chinese patent medicine, the main efficacy is to clear away heat and toxic material. Comprises artificial bezoar, Realgar, Gypsum Fibrosum, radix et rhizoma Rhei, Scutellariae radix, radix Platycodi, Borneolum Syntheticum, and Glycyrrhrizae radix. As a heat clearing agent, the Chinese medicinal composition has the effects of clearing heat and removing toxicity. Can be used for treating excessive fire-heat, sore throat, gingival swelling and pain, aphtha of the mouth and tongue, and conjunctival congestion and swelling and pain.
Dexamethasone tablets, 0.75 mg/tablet. The indications are adrenocortical hormone drugs. Is mainly suitable for allergic and autoimmune inflammatory diseases, such as connective tissue diseases, severe bronchial asthma, allergic diseases such as dermatitis, etc., ulcerative colitis, acute leukemia, malignant lymphoma, etc. The medicine is also used for diagnosing some adrenal cortex diseases, namely a dexamethasone inhibition test.
The metronidazole tablet is 0.2 g/tablet and is mainly used for killing anaerobic bacteria in the oral cavity. The indications are used for treating intestinal and parenteral amebiasis (such as amebiasis liver abscess, pleural amebiasis and the like). Can also be used for treating trichomonas vaginalis, venosasis, leishmaniasis, and filarial infection. It is also widely used for treating anaerobic bacterial infection.
Pain-relieving tablets, 0.5 g/tablet, are mainly used for easing pain. The ingredients comprise aminopyrine, phenacetin, caffeine, and phenobarbital. The indications are fever and mild and moderate pain.
The vitamin B complex is a compound preparation, adopts a tablet shape, and contains vitamin B1, vitamin B2, vitamin B6, nicotinamide and calcium pantothenate. The vitamin B complex participates in the metabolism process of organisms, and provides coenzyme necessary for various metabolic links in vivo and important coenzyme raw materials for tissue respiration. Nicotinamide is a component of coenzyme I and II, participates in biological oxidation, and plays a role in hydrogen transfer. Vitamin B6 produces a physiologically active substance together with ATP in vivo, is a prosthetic group of various enzymes, and participates in the metabolism of amino acids and fats. Calcium pantothenate is a coenzyme A precursor, participates in sugar, fat and protein metabolism, and plays a role in acyl transmission in metabolism.
The vitamin C is prepared into tablet, each tablet contains 0.1g of vitamin C, and the components also comprise starch and magnesium stearate. The indications are used for preventing scurvy, and can also be used for the adjuvant treatment of various acute and chronic infectious diseases, purpura and the like. Vitamin C is involved in antibody and collagen formation in the body, tissue repair (including some redox actions), metabolism of phenylalanine, tyrosine, folic acid, utilization of iron, carbohydrates, synthesis of fat, protein, and maintenance of immune function, hydroxylation of 5-hydroxytryptamine, maintenance of vascular integrity, and promotion of absorption of non-heme iron.
The capsule for promoting blood circulation and dredging collaterals is prepared from Chinese medicinal capsule prepared by Shanxi cloud pharmaceutical Limited liability company. The capsule is filled with 0.25g per capsule, and has the following main functional indications: break blood and remove stasis, activate blood and remove stasis, relieve menalgia, dredge vessels and alleviate pain. Can be used for treating abdominal mass, blood stasis, amenorrhea, traumatic injury and hyperlipidemia, manifested by vertigo, chest distress, heart pain, and obesity due to phlegm and blood stasis. The main component of the medicine is leech.
The invention also provides a preparation method of the pharmaceutical composition for treating oral ulcer, which comprises the following steps: weighing acyclovir tablets, bezoar detoxicating tablets, blood circulation promoting and blood circulation promoting capsules, dexamethasone tablets, metronidazole tablets and pain relieving tablets as well as vitamin B complex and vitamin C of auxiliary materials according to the proportion, respectively grinding the tablet medicines and capsule contents into powder, sieving and uniformly mixing to obtain the required pharmaceutical composition.
Preferably, the particle size of the sieved medicinal powder is 30-40 meshes.
The pharmaceutical composition is kept in bulk, bottled and sealed, or filled into capsules, or tableted, and finally packaged for later use.
The pharmaceutical composition for oral ulcer and the preparation method thereof provided by the present invention will be further described with reference to the following examples.
Examples 1 to 4
In each example, the pharmaceutical composition was prepared according to the raw material composition ratios shown in table 1 below. All the raw materials respectively accord with the corresponding national standards.
Table 1 formulation table of pharmaceutical compositions (in parts by weight).
Figure BDA0003571492260000041
Figure BDA0003571492260000051
The invention also provides a preparation method of the pharmaceutical composition of each embodiment.
Weighing acyclovir tablets, bezoar detoxicating tablets, blood circulation promoting and blood circulation promoting capsules, dexamethasone tablets, metronidazole tablets and pain relieving tablets as well as vitamin B complex and vitamin C of auxiliary materials according to the proportion, respectively grinding the tablet medicines and capsule contents into powder, sieving and uniformly mixing to obtain the required pharmaceutical composition. Preferably, the particle size of the sieved medicinal powder is 30-40 meshes. The pharmaceutical composition is kept in bulk, bottled and sealed, or filled into capsules, or tableted, and finally packaged for later use.
Thousands of clinical experiments prove that the pharmaceutical composition for treating the oral ulcer has the effective rate of over 99 percent and the cure rate of 98.4 percent. In the treatment process, the composition can quickly diminish inflammation, relieve pain, clear away heat and toxic materials, repair oral mucosa, reduce pain of patients and shorten the healing time.
While the present invention has been described in detail with reference to the preferred embodiments, it should be understood that the above description should not be taken as limiting the invention. Various modifications and alterations to this invention will become apparent to those skilled in the art upon reading the foregoing description. Accordingly, the scope of the invention should be determined from the following claims.

Claims (8)

1. A pharmaceutical composition for oral ulcer, comprising:
acyclovir tablets, bezoar detoxicating tablets, blood circulation promoting and blood circulation promoting capsules, dexamethasone tablets, metronidazole tablets and pain relieving tablets.
2. The pharmaceutical composition for treating oral ulcer according to claim 1, wherein the pharmaceutical composition comprises the following components in parts by weight: 80-120 parts of acyclovir tablets, 80-120 parts of bezoar detoxicating tablets, 40-60 parts of blood-activating and vessel-dredging capsules, 40-60 parts of dexamethasone tablets, 20-30 parts of metronidazole tablets and 20-30 parts of pain-relieving tablets.
3. The pharmaceutical composition for treating oral ulcer according to claim 2, wherein the weight ratio of acyclovir tablets, bezoar detoxicating tablets, blood circulation promoting and vein relaxing capsules, dexamethasone tablets, metronidazole tablets and pain relieving tablets in the pharmaceutical composition is 1:1:0.5:0.5:0.25: 0.25.
4. The pharmaceutical composition for treating oral ulcer according to claim 2, further comprising an adjuvant, wherein the adjuvant comprises vitamin B complex and vitamin C.
5. The pharmaceutical composition for treating oral ulcer according to claim 4, wherein the auxiliary materials comprise, in parts by weight: 6-10 parts of vitamin B complex and 5-8 parts of vitamin C.
6. A method for preparing a pharmaceutical composition for oral ulcer according to any one of claims 1 to 5, wherein the method comprises: weighing acyclovir tablets, bezoar detoxicating tablets, blood circulation promoting and blood circulation promoting capsules, dexamethasone tablets, metronidazole tablets and pain relieving tablets as well as vitamin B complex and vitamin C of auxiliary materials according to the proportion, respectively grinding the tablet medicines and capsule contents into powder, sieving and uniformly mixing to obtain the required pharmaceutical composition.
7. The method of claim 6, wherein the sieved powder has a particle size of 30-40 mesh.
8. The method for preparing a pharmaceutical composition for oral ulcer according to claim 6, wherein the pharmaceutical composition is kept in bulk and bottled for sealing, or filled into capsules, or subjected to tabletting process, and finally packaged for use.
CN202210320631.6A 2022-03-29 2022-03-29 Pharmaceutical composition for treating oral ulcer and preparation method thereof Pending CN114652762A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210320631.6A CN114652762A (en) 2022-03-29 2022-03-29 Pharmaceutical composition for treating oral ulcer and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210320631.6A CN114652762A (en) 2022-03-29 2022-03-29 Pharmaceutical composition for treating oral ulcer and preparation method thereof

Publications (1)

Publication Number Publication Date
CN114652762A true CN114652762A (en) 2022-06-24

Family

ID=82032880

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210320631.6A Pending CN114652762A (en) 2022-03-29 2022-03-29 Pharmaceutical composition for treating oral ulcer and preparation method thereof

Country Status (1)

Country Link
CN (1) CN114652762A (en)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
吴丽莉等: "甲硝唑加地塞米松治疗复发性口腔溃疡", 《中国抗生素杂志》 *
孟宪花: "复合口腔溃疡粉治疗60例口腔溃疡效果分析", 《全科口腔医学电子杂志》 *
杨光: "牛黄解毒片联合西药治疗复发性口腔溃疡的临床应用", 《中国民族民间医药》 *

Similar Documents

Publication Publication Date Title
CN109452521B (en) Auxiliary uric acid peptide reducing solid beverage, preparation method and application
CN1931197A (en) Health product and medicine containing glossy ganoderma and selenium
US6287576B1 (en) Biostimulating agent
US20030044512A1 (en) Liver function improvement formulation
CN101744924B (en) Multiple-effect Chinese herbal medicine compound of bacterial diseases of turbot
KR20120010464A (en) Composition having herb extract as active incredient for treating hangover and preparation method thereof
CN1799409A (en) Diet fiber composition with fat-reducing face-beautifying functions and its production method
CN108813610A (en) A kind of saussurea involucrata composition and its application for improving immunity
CN100431568C (en) Chinese medicine for treating puerperal hypogalactia
CN114652762A (en) Pharmaceutical composition for treating oral ulcer and preparation method thereof
JP6980791B2 (en) Composition for the prevention or treatment of gastritis or gastric ulcer
CN109673906A (en) A kind of composite food fiber powder and preparation method thereof
JP4791358B2 (en) Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superinfection and fungal recurrence
CN101480412A (en) Honeybee four-treasure for treating prostatosis
US4650668A (en) Composition for relieving toothache pain and other forms of intense pain
CN107582866B (en) Application method of dendrobium officinale and amlodipine in preparation of medicine for treating hypertension
CN107753716B (en) Active composition for treating chronic urticaria based on multi-target intervention and preparation method thereof
CN100589814C (en) Antihyperglycemic antisenescence medicinal composition and method for preparing the same
CA2518738A1 (en) Method and composition for preventing or reducing diarrhea
KR20190012943A (en) Health functional food composition for Burning mouth syndrome and Stomatitis Treatment and Prevention
JP7505831B2 (en) Hypertension improving agent containing seaweed extract, and functional foods, quasi-drugs and medicines containing said hypertension improving agent
CN109568340B (en) Medicine for treating stomatitis
CN114982970B (en) Nutrient buccal tablet for assisting in protecting inner cavity mucosa and preparation method thereof
CN112791166B (en) Medicinal and edible composition for enhancing muscle performance and relieving exercise-induced fatigue
CN106177269A (en) The pharmaceutical composition of quick curing oral keritonocytes, preparation method and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination